IMPROVE TRIAL: Berinert for Deceased-Donor Kidney Transplant Outcomes
This study, called the IMPROVE TRIAL, is investigating whether a medication called Berinert can improve how well a transplanted kidney works in the first year after surgery. It's for adults aged 18 to 75 who are on dialysis and waiting for a deceased donor kidney transplant. Participants will receive either Berinert or a placebo (an inactive substance that looks the same) as an infusion into the kidney before transplantation. The main goal is to see if Berinert leads to better kidney function 12 months after the transplant. The study aims to enroll 180 participants, but its current status is unclear.
- Study design
- This is an interventional study comparing Berinert to a placebo. Neither you nor the study doctor will know which treatment you receive. The study plans to enroll 180 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your kidney function will be measured at 12 months post-transplantation.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)
At a glance
Conditions
Where it's being run
4 sites across 4 statesStudy leadership
- Peter S Heeger, MD · STUDY_CHAIR · Cedars-Sinai Medical Center
- Sindhu Chandran, MBBS, MD · STUDY_CHAIR · Cedars-Sinai Medical Center
- Stanley Jordan, MD · STUDY_CHAIR · Cedars-Sinai Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Difference between study arms in renal functionAt 12-months post-transplantation
Measured as Estimated Glomerular Filtration Rate Chronic Kidney Disease Epidemiology Collaboration (eGFRCKD-EPI) in ml/min/1.73m\^2